A retrospective , multicenter study analyzing role of partial response and resistance to first gen-SSA in the choice of second line treatments and their outcomes
Latest Information Update: 09 Nov 2022
At a glance
- Drugs Pasireotide (Primary) ; Pegvisomant (Primary)
- Indications Acromegaly
- Focus Therapeutic Use
Most Recent Events
- 09 Nov 2022 New trial record
- 01 Nov 2022 Results published in the Endocrine